The Effect of Intravitreal Injection of Avastin for Neovascular Age related Macular Degeneration

Objective: To determine the effect of intravitreal injection of Avastin for\r\n Neovascular age related macular degeneration.\r\nMethods: 76 Patients were selected by sampling. Visual acuity was evaluated by\r\n Snellen chart at a distance of 6 meters with good light and single eye. Accordingly,\r\n logarithm of Minimum Angle of Resolution (MAR) was recorded. Avastin (1.25\r\n mg) in 0.05 ml of liquid was injected with a sterile syringe and needle. Second and\r\n third injections were repeated one month after the first injection.\r\nResults: The results of Visual acuity (VA) in the patients (In log MAR): Mean ± SD\r\n of visual acuity (VA) in patients before the study was 0.906 ± 0.080, One month\r\n after injection was 0.818 ± 0.097, 3 months after injection was 0.6 ± 0.126 and 6\r\n months after injection was 0.488 ± 0.164.\r\nConclusion: Intravitreal avastin (1.25 mg) is well tolerated and associated with\r\n improvement in VA and decreased retinal thickness by OCT and also reducing\r\n angiographic leakage in most of the patients. Decreasing BFVs in all retrobulbar\r\n arteries, suggests that avastin exerts a short‐term regional effect.